Bayesian Population Physiologically-Based Pharmacokinetic (PBPK) Approach for a Physiologically Realistic Characterization of Interindividual Variability in Clinically Relevant Populations
Open Access
- 2 October 2015
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (10) , e0139423
Abstract
Interindividual variability in anatomical and physiological properties results in significant differences in drug pharmacokinetics. The consideration of such pharmacokinetic variability supports optimal drug efficacy and safety for each single individual, e.g. by identification of individual-specific dosings. One clear objective in clinical drug development is therefore a thorough characterization of the physiological sources of interindividual variability. In this work, we present a Bayesian population physiologically-based pharmacokinetic (PBPK) approach for the mechanistically and physiologically realistic identification of interindividual variability. The consideration of a generic and highly detailed mechanistic PBPK model structure enables the integration of large amounts of prior physiological knowledge, which is then updated with new experimental data in a Bayesian framework. A covariate model integrates known relationships of physiological parameters to age, gender and body height. We further provide a framework for estimation of the a posteriori parameter dependency structure at the population level. The approach is demonstrated considering a cohort of healthy individuals and theophylline as an application example. The variability and co-variability of physiological parameters are specified within the population; respectively. Significant correlations are identified between population parameters and are applied for individual- and population-specific visual predictive checks of the pharmacokinetic behavior, which leads to improved results compared to present population approaches. In the future, the integration of a generic PBPK model into an hierarchical approach allows for extrapolations to other populations or drugs, while the Bayesian paradigm allows for an iterative application of the approach and thereby a continuous updating of physiological knowledge with new data. This will facilitate decision making e.g. from preclinical to clinical development or extrapolation of PK behavior from healthy to clinically significant populations.Keywords
This publication has 58 references indexed in Scilit:
- Using Bayesian-PBPK modeling for assessment of inter-individual variability and subgroup stratificationIn Silico Pharmacology, 2013
- In silico pharmacology: drug design and discovery’s gate to the futureIn Silico Pharmacology, 2013
- Addressing Human Variability in Next-Generation Human Health Risk Assessments of Environmental ChemicalsEnvironmental Health Perspectives, 2013
- A Mechanistic, Model‐Based Approach to Safety Assessment in Clinical DevelopmentCPT: Pharmacometrics & Systems Pharmacology, 2012
- Population Pharmacokinetics and Pharmacodynamics of Ribavirin in Patients with Chronic Hepatitis C Genotype 1 InfectionThe AAPS Journal, 2012
- Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects ModelsThe AAPS Journal, 2011
- A Computational Systems Biology Software Platform for Multiscale Modeling and Simulation: Integrating Whole-Body Physiology, Disease Biology, and Molecular Reaction NetworksFrontiers in Physiology, 2011
- Whole-body physiologically based pharmacokinetic population modelling of oral drug administration: inter-individual variability of cimetidine absorptionJournal of Pharmacy and Pharmacology, 2009
- Physiological Pharmacokinetic Analysis Using Population Modeling and Informative Prior DistributionsJournal of the American Statistical Association, 1996
- Markov Chain Monte Carlo Convergence Diagnostics: A Comparative ReviewJournal of the American Statistical Association, 1996